MedCity News June 28, 2020
Alaric DeArment

AstraZeneca’s Phase III AURA3 trial of the lung cancer drug Tagrisso was chosen for the program, Project Patient Voice. However, an FDA spokesperson said no new trials would be added in the coming weeks or months.

The U.K.’s largest drug company is the first to be included in a new Food and Drug Administration pilot program designed to make patient-reported outcomes from cancer clinical trials available to the public.

The FDA launched Project Patient Voice last week, with London-based AstraZeneca as the first participant. The first clinical trial listed is AURA3, a study of 419 patients originally launched in 2014 that compared the non-small cell lung cancer drug Tagrisso against platinum chemotherapy. The trial included the use of the Patient...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech
Related Articles:
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
Pfizer hemophilia gene therapy arrives in US to uncertain future
Early tests of H5N1 prevalence in milk suggest U.S. bird flu outbreak in cows is widespread
Bird Flu (H5N1) Explained: Here’s What To Know—And Why Scientists Are Concerned
2023 Had Most Food Recalls Since Start Of COVID-19 Pandemic, Report Finds

Share This Article